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Efficacy of 15-deoxyspergualin in Canine Lung Transplantation
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The First Department of Surgery, Nagasaki University School of Medicine
 Deoxyspergualin (DSG) is a new immunosuppressive 
agent derived from the bacterium Bacillus laterosporus. In 
this study, we evaluated the immunosuppressive efficacy of 
DSG in cases of canine lung allotransplantation and the 
influence of DSG on bronchial anastomotic healing. Twenty-
four adult mongrel dogs underwent left lung transplantation. 
The animals were classified into four groups. Group 1 (n = 
4) dogs received DSG dosage of 4.8 to 1.2 mg/kg/day. Group 
2 (n = 7) dogs received DSG dosage of 0.8 mg/kg/day. 
Group 3 (n = 6) dogs were administered a combination 
therapy consisting of 0.5 mg/kg/day and 10 mg/kg/day of 
DSG and cyclosporin A (CsA), respectively. Group 4 (n = 7) 
dogs served as controls, receiving 10 mg/kg/day of CsA. 
Acute rejection was almost completely suppressed in Group 
1 dogs, but severe toxic side effects including emaciation, 
diarrhea, and pulmonary congestion were often observed. In 
the grafted lungs of Group 2 dogs, minimal rejection oc-
curred, but improved within three weeks after surgery. A 
mononuclear cell infiltration characteristically appeared 
around the bronchus rather than around the vessels. Grafted 
lung rejection was suppressed sufficiently in Group 3 dogs. 
However, multiple lung abscesses were found in both the 
grafted and native lungs of these dogs. Pseudomonas 
aeruginosa was isolated in a bacterial culture study. Side 
effects such as gastrointestinal disturbances were mild. The 
bronchial mucosal blood flow in recipient dogs was meas-
ured by a laser Doppler velocimetry. The blood flow did not 
decrease markedly in the dogs of Groups 2 and 4. In contrast, 
the blood flow of dogs in Groups 1 and 3 was significantly 
reduced. These data suggest that DSG is an effective 
immunosuppressive agent in canine lung allotransplan-
tation. However, the DSG dosages for clinical use will 
require further study. This is especially true for cases of 
single use or when DSG is used in combination therapy.
INTRODUCTION 
 Since cyclosporin A (CsA) was introduced for the use in 
clinical organ transplantation, lung transplantation has 
become an increasingly effective modality for the treat-
ment of endstage lung diseases. Nevertheless, lung rejec-
tion remains a serious problem. Therefore, it is necessary 
to develop new immunosuppressive agents and strategies 
that are more potent and less toxic. Deoxyspergualin
(DSG) is a new immunosuppressive agent derived from the 
bacterium Bacillus laterosporus. In experimental organ 
transplantation, DSG has prolonged the survival of 
skin 1)2), liver')'), heart')'), and kidney') grafts in rats. The 
effects of DSG on renal allotransplantation in various 
animals have been evaluated by many researchers. DSG 
treatment has prolonged graft survival and successfully 
reversed cases of acute rejection"'. The use of DSG in 
lung transplantations has been reported previously only 
once in a series of experimental rat lung transplantations 
that has been described by Katayama et al. 1') In this study, 
determination of the optimal dose of DSG was attempted 
in canine lung transplantation, evaluating its effective-
ness, adverse effects, and influence on bronchial 
anastomotic healing.
MATERIALS AND METHODS 
 Forty-eight adult mongrel dogs of either sex, weighing 8 
to 15 kg, were kindly supplied from the animal center for 
biomedical research of the Nagasaki University School of 
Medicine and used in this study, A left-sided, single-lung 
transplantation was performed in 24 dogs using a method 
similar to that which has been described by Veith and 
Richards12) The left bronchus was anastomosed with 4-0 
prolene continuous sutures, just proximal to the bifurca-
tion of the upper and lower bronchus of the donor lung. 
Bronchial omentopexy was routinely performed as has 
been described by Dubois et al. 13) The dogs were monitored 
with daily radiographs and weekly blood cell counts. 
Fiberoptic bronchoscopy was performed every week with 
the dog under general anesthesia to assess bronchial 
anastomotic healing. The bronchial mu-cosal blood flow 
was assessed using laser Doppler velocimetry. Simultane-
ously, lung specimens were obtained during thoracotomy. 
The extent of acute rejection of the grafted lung was 
confirmed histologically. Acute lung rejection was classi-
fied according to Yousem's classifications'). The dogs were 
housed in the animal facility of the Nagasaki Animal 
Center. During the study, all animals received care based 
on the guidelines for animal experiments of the Nagasaki
University School of Medicine. 
Experimental groups 
 The animals were classified into four groups as follows: 
Group 1 (n = 4). After transplantation, the animals 
                 were administered intravenous DSG at 
               dosage of 4.8 mg/kg/day for the first
               two days, 2.4 mg/kg/day for the next
               two days, and 1.2 mg/kg/day for the
                following three days. Thereafter, the
                drug administration was discontinued.
             (DSG high dose) 
Group 2 (n = 7). The animals were treated with 
               intravenous DSG administered at a
               dosage of 0.8 mg/kg/day for three
                weeks after the transplantation. (DSG 
                 low dose) 
Group 3 (n = 6). The animals were administered 
                 intravenous DSG and intramuscular 
               CsA, at dosages of 0.5 mg/kg/day and 
               10 mg/kg/day, respectively, for three
                weeks after the transplantation.
              (Combination) 
Group 4 (n = 7). The animals were administered 
                 intramuscular CsA at a dosage of 10 
               mg/kg/day for three weeks after the
                transplantation. (Control) 
 DSG was supplied from the Nippon-Kayaku Phar-
maceutical Co. (Tokyo, Japan). 
 All recipient dogs received subcutaneous injections of 
penicillin or cephalosporin during the experimental postop-
erative period. 
  Animals suffering from severe diarrhea or anorexia were 
administered 300 mL/day of subcutaneous or intravenous 
lactated Ringer's solution. 
 The dogs were killed within three weeks of the surgery. 
The lungs and bronchi of these dogs were fixed in 10 % 
neutral formalin, embedded in paraffin, and cut into 5 ,u m 
thick sections. These sections were then stained with 
hematoxylin-eosin for light microscopic examination. 
Measurement of bronchial mucosal blood flow by laser 
Doppler velocimetry (LDV) 
 The bronchial mucosal blood flow (MBF) in recipient 
dogs was measured by a laser flowmeter (ALF 2100, 
Advance Co, Ltd, Japan). Measurements were made with 
a probe inserted through a fiberoptic bronchoscope that 
was applied to the membranous portion of the carina and 
the first bronchial bifurcation of the transplanted lung. 
Five blood flow estimations were made at each site. The 
mean value of these estimations was regarded as the 
measured blood flow value. It took 10 seconds to obtain 
each estimation. Measured values were calculated as 
follows:
 L/C ratio = MBF at the first bifurcation of the left 
bronchus / MBF at the carina 
 To eliminate the influence of acute rejection, only the 
values for rejection grades 0 and 1 were used. 
Statistics 
 Statistical significance was determined by Wilcoxon 




 There were no operative deaths. Rejection occurred in 
only one Group 1 dog during the DSG therapy. However, in 
the others of Group 1 dogs, rejection occurred within four 
days after discontinuing the DSG treatment. There was no 
tolerance or prolonged effects. All dogs became emaciated, 
and two dogs were anorexic from postoperative day 4 to 
day 5. Two dogs died of malnutrition on day 7. The 
remaining two dogs were killed on postoperative days 11 
and 14, because of prominent signs of rejection. 
 Minimal signs of rejection occurred in six of the seven 
Group 2 dogs. Rejection did not occur in the remaining 
dog. A severe gastrointestinal disturbance, resulting from 
DSG administration, also occurred in this group. Anorexia 
occurred in six of the dogs, and diarrhea occurred in four 
of the dogs. Five dogs died of malnutrition, intus-
susception, and thrombosis between days 7 to 15. The 
remaining two dogs were killed on days 7 and 17. 
 In four of the six Group 3 dogs, histologic findings 
consistent with rejection were not found. However, in the 
remaining two dogs, the finding of minimal rejection was 
present. Mild malnutrition also was observed in this 
group. The incidence of anorexia or diarrhea in Group 3 
dogs was rare compared with that in Group 1 and Group 2 
dogs. Three dogs died of malnutrition between day 7 and 
11. Two dogs were killed, one each on days 13 and 16. Only 
one Group 3 dog survived for 21 days. 
  Five of the seven Group 4 dogs experienced rejection of 
their grafted lungs. A CsA dosage of 10 mg/kg was not 
enough to suppress the allograft rejection in this model. 
However, the general condition of these dogs was better 
than that of any other group. Two dogs died because of 
intussusception and acute rejection between days 8 and 12. 
Five dogs were killed between days 14 and 21 after surgery 
(Table 1).
Table 1. Results of canine lung transplantation
Group Grade` of Survial Cause of death Side effects 
       acute rejection (days) Anorexia Diarrhea 
Group 1 0 14 Killed - -
           0 11 Killed + -
             2 7 Malnutrition + -
              0 7 Malnutrition - -
Group 2 1 7 Killed + + 
              1 7 Malnutrition + -
              1 15 Malnutrition + +
              1 14 Intussusception + +
             0 10 Thrombosis + +
             1 12 Malnutrition + -
             1 17 Killed - -
Group 3 0 8 Malnutrition + -
             0 7 Malnutrition + -
            0 16 Killed - -
              1 11 Malnutrition - -
            1 13 Killed - -
             0 21 Killed - -
Group 4 0 8 Intussusception + -
              4 12 Rejection - -
             1 14 Killed - -
             0 21 Killed - -
             4 17 Killed - -
            0 21 Killed - -
            1 21 Killed - -
          * last day of drug administration (Yousem's classification)
Fig. 1. Photomicrograph of a grafted lung from a dog 
      in Group 1 on postoperative day 7 (H-E stain, X100). 
      Alveolar edema and bleeding can be observed.
Histologic examinations of grafted lungs 
 Signs of pulmonary edema were observed in the lungs of 
all Group 1 dogs (Fig. 1). 
 In six of the seven Group 2 dogs, the grafted lungs 
showed minimal evidence of rejection. However, advanced 
signs of rejection were not seen. The density of the 
perivascular or peribronchial cuffing had markedly de-
creased at the time of death. Mononuclear cell 
infiltrations were remarkable around the bronchi rather 
than around the vessels (Fig. 2). Bronchopneumonia was 
present in two cases. 
 Rejection did not occur in four of the six Group 3 dogs. 
However, multinodular lung abscesses were found (Fig. 3). 
Abscesses were also found in the native lungs, but were not 
present in the livers, spleens, and kidneys. Pseudomonas 
aeruginosa was isolated in a bacterial culture study. In the 
remaining two dogs, signs of minimal rejection were 
present, and a focal mononuclear cell infiltration was 
sparsely seen at the subpleural, perivascular, and 
peribronchial sites (Fig. 4). 
  No remarkable findings were seen in the lungs of Group 
4 dogs, except signs of rejection.
Fig. 2. Photomicrograph of a grafted lung from a dog in 
       Group 2 on postoperative day 7 (H-E stain, X 40). 
       A mononuclear cell infiltration is apparent around 
       the bronchus rather than around the vessels.
Bronchoscopic findings of the bronchial anastomosis 
 Severe stenosis or dehiscence of the bronchial ana-
stomosis was not observed in any of the groups. In all 
Group 1 and 3 dogs, the bronchial mucosa adjacent to the 
anastomosis revealed erythema, edema, and ulcers, consis-
tent with a severe inflammatory response, on bronch-
ofiberscopic examination. 
 In contrast, the healing of the bronchial anastomosis 
was superb in all Groups 2 and 4 dogs. Bronchial mucosal 
inflammation was minimal, with only mild erythema 
observed, in 60 % of the dogs. 
Microscopic findings of the bronchial anastomosis 
 Microscopic findings at the site of the bronchial 
anastomosis in Groups 1 and 3 dogs revealed severe 
mononuclear and neutrophil cell infiltrations. Ulcers,
Fig. 3a Photograph of a grafted lung from a dog in Group 3 
       on postoperative day 7 
       Multinodular lung abscesses can be seen
Fig. 3b. Photomicrograph of a grafted lung from a dog in 
       Group 3 on postoperative day 7 (H-E stain, X 20) 
        Lung abscesses are visible
Fig 4a. Photomicrograph of a grafted lung from a dog in 
       Group 3 on postoperative day 7 (H E stain, X 20) 
       A focal mononuclear cell infiltration can be seen at 
       the peribronchial site
Fig 4b. Photomicrograph of a grafted lung from a dog in 
       Group 3 on postoperative day 7 (H-E stain, X 100)
       A focal mononuclear cell infiltration is visible at the 
        perivascular site
Fig. 5. Photomicrograph of the bronchial anastomosis of a 
       Group 3 dog on postoperative day 7 (H-E stain, X
       40) Mononuclear cell and neutrophil infiltrations 
        are remarkable Ulcers, degenerative necrosis, 
       bleeding, and edema also can be observed
Fig. 6. Photomicrograph of the bronchial anastomosis of a 
       Group 2 dog on postoperative day 7 (H-E stain, X
      40) Although bleeding and mild edema are pre-
       sent, the epithelium is preserved, and a plasmocyte
       infiltration dominates
Fig. 7. Bronchial mucosal blood flow measured by laser Doppler velocimetry 
       L/C ratio: The blood flow at the left main bronchus / The blood flow at the carina
degenerative necrosis, bleeding, and edema also were 
noted. Anastomotic healing was retarded (Fig. 5). 
 The bronchial anastomotic healing went well in Groups 
2 and 4 dogs. Although bleeding and mild edema were seen, 
the epithelium was preserved and there was a dominant 
plasmocyte infiltration (Fig. 6). 
Bronchial mucosal blood flow 
 The bronchial mucosal blood flow of Group 1, described 
as the L/C ratio, decreased to 0.66±0.12 one week after 
surgery (Fig. 7). 
 The L/C ratio of Group 2 was 0.95 ± 0.33 for the first 
week, and 0.94±0.25 for the second week. Those in Group 
3 was 0.64±0.12 for the first week, 0.54+0.07 for the 
second week, and 0.59±0.14 for the third week. And also 
those in Group 4 was 0.95±0.16 for the first week, 0.81 ± 
0.12 for the second week, and 0.79±0.10 for the third week. 
 These values for Groups 1 and 3 were significantly lower 
than those of Group 4 for the first and second week. 
Complications in DSG-treated dogs 
 Dose-dependent signs of DSG toxicity included gastroin-
testinal disturbances (anorexia, diarrhea, and vomiting) 
and bone marrow depression. The incidence of anorexia 
was 59 %, and the incidence of diarrhea was 24 % in all
dogs. Leukocytopenia (WBC<4,000/mm8) occurred in 38% 
of the dogs, and thrombocytopenia (platelets <10 X 104) 
occurred in 71 % of the dogs.
DISCUSSION 
 The substance 15-deoxyspergualin (DSG) is a 15-deoxy 
analogue of spergualin that was isolated from the culture 
filtrate of Bacillus laterosporus in 1981 15)16)1') . This sub-
stance has been reported to have an immunosuppressive 
effect in various experimental organ transplantation 
models 18)6) The mechanism of action of DSG remains 
unknown, although it is believed to be different from that 
of cyclosporine A (CsA) or FK506. DSG suppresses both 
cellular immunity and humoral immunity"). Therefore, 
DSG is applied often to xenotransplantation models. In 
contrast to CsA or FK 506, DSG does not suppress 
blastogenic responses and the release of IL-1 and IL-2 in 
response to mitogens. It works to suppress the induction of 
secondary CTL in vitro and in vivo '> . In addition to a 
different immunopharmacologic mode of action, the most 
remarkable difference between DSG and CsA is that 
long-term graft survival can be achieved more easily by 
initiating DSG administration at the onset of graft 
rejection rather than by initiating it at the time of trans-
plantation.
  DSG has a dose-dependent immunosuppressive effect on 
dog kidney transplantation. Amemiya et al'). have re-
ported that a DSG dosage of 0.6 to 0.8 mg/kg/day is 
appropriate for beagles with kidney transplantations. This 
dosage takes into consideration the side effects of the 
drug, which mainly manifest as gastrointestinal distur-
bances. Histologic study and laboratory analysis further 
indicate that 0.6 mg/kg/day of DSG is the ctirical dosage 
for immunosuppression. Therefore, we adopted the DSG 
dosage of 0.8 mg/kg/day. We also administered a higher 
DSG dosage of 4.8 - 1.2 mg/kg/day which was attempted 
to reverse ongoing rejection"). Furthermore, the combina-
tion usage of DSG and CsA was promoted for lung trans-
plantation. In the combination therapy, DSG and CsA 
dosages of 0.5 mg/kg/day and 10 mg/kg/day respectively, 
which are insufficient for a single use, were used. 
  In this study, rejection was almost completely sup-
pressed by the administration of 4.8 - 1.2 mg/kg/day of 
DSG, but severe toxicities such as emaciation, diarrhea, 
and pulmonary congestion were often observed. Therefore, 
this DSG dosage is considered to be an overdose. 
 The DSG dosage of 0.8 mg/kg/day had an almost 
sufficient immunosuppressive effect. Grafted lungs 
treated with this dosage showed minimal rejection, but the 
density of perivascular and peribronchial cuffing had 
markedly decreaded when the dogs were killed. Therefore, 
this dosage appears to be sufficient for maintenance use, 
but insufficient for early prophylactic use. 
 Combination therapy with DSG and CsA provided a 
strong immunosuppressive effect. Side effects such as 
gastrointestinal disturbances were mild, but serious 
pulmonary infections were observed. Further studies will 
be required prior to the clinical use of such combination 
therapy. 
 Bronchial anastomotic complications have been a great 
concern in clinical cases of lung transplantation. Most 
anastomotic complications are caused by bronchial 
ischemia and prolonged anastomotic healing that is often 
affected by an immunosuppressant. Methylprednisolone 
and azathioprine significantly affect bronchial 
anastomosis wound healing. However, CsA has advanta-
geous effects on bronchial healing"). Bronchial ana-
stomosis healing depends largely on the regional blood 
flow. A close relationship has been observed between 
healing at the anastomotic site and the amount of regional 
blood flow measured with LDV23). Oikawa has reported 
that DSG inhibits angiogenesis in a dose-dependent man-
ner 24) 
. 
 In our study, the L/C ratio did not decrease markedly in 
the Group 2 dogs (0.8 mg/kg/day of DSG) and in the 
Group 4 dogs (10 mg/kg/day. of CsA). The presence of a 
sufficient blood flow was demonstrated, and bronchial 
healing was satisfactory. In contrast, the bronchial 
anastomotic healing was retarded in the Group 1 dogs 
(initial DSG dosage of 4.8 mg/kg/day) and in the Group 3
dogs (combination therapy with DSG and CsA). In these 
dogs, the L/C ratio was reduced and the inflammatory 
response of the bronchial anastomosis was macroscopi-
cally and microscopically severe. 
 The severity of the DSG-induced toxic side effects may 
vary according to species and may be only mild in human 
and rats. DSG can be administered to rats at a dosage 
eight times higher than that in dogs"). It has been reported 
that DSG administration in renal transplantation patients 
does not cause serious side effects"')). In our study, the 
toxicity of DSG was unexpectedly troublesome. In our dogs 
treated with high dosage of DSG, pulmonary congestion 
and edema were observed. Ito has reported that interstitial 
pneumonia, bronchiolitis, and pulmonary edema were 
observed in dog lungs treated with DSG29'. 
 In conclusion, DSG serves as a strong immunosup-
pressant in canine lung allotransplantation. However, 
further dosage studies are necessary prior to its clinical 
use. This is especially true in the case of combination 
therapy with CsA and DSG, which can cause severe pulmo-
nary infections, pulmonary congestion, and poor bronchial 
anastomotic healing.
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